ClinicalTrials.Veeva

Menu

Ultra-low-dose Chest CT for HHT

Mayo Clinic logo

Mayo Clinic

Status

Active, not recruiting

Conditions

Hereditary Hemorrhagic Telangiectasia

Treatments

Diagnostic Test: Ultra-low dose chest CT

Study type

Observational

Funder types

Other

Identifiers

NCT04874558
21-000324

Details and patient eligibility

About

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Enrollment

10 estimated patients

Sex

All

Ages

1 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Ages 1 to 17 years
  • Diagnosed with positive HHT causing mutations or based on Curacao criteria

Exclusion criteria

  • Acute respiratory distress
  • Unstable cardiovascular status
  • Pneumothorax, hemoptysis
  • Pulmonary edema
  • Pulmonary emboli
  • Fractured ribs or other chest trauma
  • Recent bronchoscopy
  • Lung transplantation

Trial design

10 participants in 1 patient group

Low-dose contrast-enhanced chest CT exam
Description:
Subjects will undergo a low-dose contrast-enhanced chest CT exam with coverage from the neck base through the lungs to the upper abdomen on a third-generation dual-source CT scanner as part of their routine clinical visit based on current guidelines.
Treatment:
Diagnostic Test: Ultra-low dose chest CT

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems